Navigation Links
Patients with EGFR exon 20 insertions have poorer prognosis
Date:1/15/2013

DENVER Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in nonsmall-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies. A recent study published in the February 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concludes that patients with EGFR exon 20 insertions have similar clinical characteristics to those with common EGFR mutations, but a poorer prognosis.

Researchers from the Dana-Farber Cancer Institute studied 1,086 patients who underwent EGFR genotyping between 2004 and 2012. No significant differences were identified between the cancers carrying exon 20 insertions and those with the common EGFR mutations. However, cancers with exon 20 insertions were more commonly seen in patients who are never-smokers and in Asian patients. Median survival of patients with exon 20 insertions was 16 months, similar to the survival of wild-type cancers and shorter than the survival of cancers with common EGFR mutations.

Given the findings, the researchers, "estimate that lung cancers with EGFR exon 20 have an annual incidence of approximately 2,000 to 4,000 patients in the United States, not dissimilar from the expected incidence of other uncommon genotype-defined subsets of NSCLC such as those with ROS1 rearrangements, BRAF mutations, or HER2 insertions."

To conclude the researchers say, "previously treated NSCLC carrying EGFR exon 20 insertions represent a population on oncogene-addicted cancers in need of targeted therapy development."


'/>"/>

Contact: Kristal Griffith
Kristal.Griffith@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer
Source:Eurekalert

Page: 1

Related biology news :

1. Reproductive health providers should discuss environmental exposure risks with patients
2. Low-calorie diet may be harmful for bowel disease patients
3. Interventional radiology: Mitigating symptoms, improving quality of life of MS patients
4. Interventional radiologists see significant symptom relief in MS patients
5. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
6. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
7. Obese patients face higher radiation exposure from CT scans -- but new technology can help
8. Researchers identified a protein useful in predicting the risk of pulmonary metastases in breast cancer patients
9. Transcatheter aortic valve implantation shows promise in patients with severe aortic stenosis
10. Urgent research needed to determine most effective follow-up care for lung cancer patients
11. Gene signature helps identify risk of relapse in lung cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited the ... the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... largest German biometrics company the two government leaders could see the three ... as DERMALOG´s multi-biometrics system.   Continue Reading ... ...
(Date:3/13/2017)... 13, 2017 Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other ... identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching on the ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... 2017   Sienna Biopharmaceuticals, Inc. , a privately ... that Richard Peterson will join the company ... Peterson, who brings more than two decades of global ... is retiring at the end of April but will ... joins Sienna from Novan, Inc., where he served as ...
(Date:3/23/2017)... BETHESDA, Md. , March 23, 2017 /PRNewswire/ ... company developing DCVax® personalized immune therapies for solid ... on the $7.5 million financing it announced last ... Company sold to several institutional investors securities totaling ... $.26 per share, and 10,000,000 shares of Class ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced ... the hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global Business ... joint development activities. , “Dr. Floyd’s career has spanned 30 years in the ...
Breaking Biology Technology: